Core Insights - Curative Biotech (CUBT) has received a Notice of Allowance for Canadian Patent Application No. 3,151,011, which focuses on a "Druggable Target to Treat Retinal Degeneration" [1] - The company holds an exclusive worldwide license for this technology through a patent license agreement with the National Eye Institute, part of the National Institutes of Health [1] - The patent includes 22 allowed claims, particularly concerning topical ocular delivery methods relevant to metformin-based formulations, aligning with the company's intended administration route [1] - The formal issuance of the patent is anticipated in the coming months [1]